162 related articles for article (PubMed ID: 33222668)
1. OSI-027 Alleviates Oxaliplatin Chemoresistance in Gastric Cancer Cells by Suppressing P-gp Induction.
Xu E; Zhu H; Wang F; Miao J; Du S; Zheng C; Wang X; Li Z; Xu F; Xia X; Guan W
Curr Mol Med; 2021; 21(10):922-930. PubMed ID: 33222668
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.
Chen BW; Chen W; Liang H; Liu H; Liang C; Zhi X; Hu LQ; Yu XZ; Wei T; Ma T; Xue F; Zheng L; Zhao B; Feng XH; Bai XL; Liang TB
Mol Cancer Ther; 2015 Aug; 14(8):1805-15. PubMed ID: 26026051
[TBL] [Abstract][Full Text] [Related]
3. The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2.
Chen B; Xu M; Zhang H; Xu MZ; Wang XJ; Tang QH; Tang JY
DNA Cell Biol; 2015 Oct; 34(10):610-7. PubMed ID: 26284306
[TBL] [Abstract][Full Text] [Related]
4. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.
Bhagwat SV; Gokhale PC; Crew AP; Cooke A; Yao Y; Mantis C; Kahler J; Workman J; Bittner M; Dudkin L; Epstein DM; Gibson NW; Wild R; Arnold LD; Houghton PJ; Pachter JA
Mol Cancer Ther; 2011 Aug; 10(8):1394-406. PubMed ID: 21673091
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro.
Zhao Q; Zhang H; Li Y; Liu J; Hu X; Fan L
J Exp Clin Cancer Res; 2010 Aug; 29(1):118. PubMed ID: 20799994
[TBL] [Abstract][Full Text] [Related]
6. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies.
Gupta M; Hendrickson AE; Yun SS; Han JJ; Schneider PA; Koh BD; Stenson MJ; Wellik LE; Shing JC; Peterson KL; Flatten KS; Hess AD; Smith BD; Karp JE; Barr S; Witzig TE; Kaufmann SH
Blood; 2012 Jan; 119(2):476-87. PubMed ID: 22080480
[TBL] [Abstract][Full Text] [Related]
7. Targeting mTORC1/2 with OSI-027 inhibits proliferation and migration of keloid keratinocytes.
Chen J; Liu K; Liu Y; Wang X; Zhang Z
Exp Dermatol; 2019 Mar; 28(3):270-275. PubMed ID: 30650200
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of Quercetin as a Multidrug-resistant Reversing Compound in Oxaliplatin-resistant Gastric-cancer Cell Lines.
Zhao G; Xue S
Altern Ther Health Med; 2023 Nov; 29(8):54-59. PubMed ID: 37652429
[TBL] [Abstract][Full Text] [Related]
9. miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.
Zhou H; Lin C; Zhang Y; Zhang X; Zhang C; Zhang P; Xie X; Ren Z
Cell Prolif; 2017 Jun; 50(3):. PubMed ID: 28217977
[TBL] [Abstract][Full Text] [Related]
10. miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathway.
Cao F; Yin LX
Exp Mol Pathol; 2019 Feb; 106():34-43. PubMed ID: 30539797
[TBL] [Abstract][Full Text] [Related]
11. LINC00963/miR-4458 regulates the effect of oxaliplatin in gastric cancer by mediating autophagic flux through targeting of ATG16L1.
Hou M; Li C; Dong S
Sci Rep; 2021 Oct; 11(1):20951. PubMed ID: 34697403
[TBL] [Abstract][Full Text] [Related]
12. Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells.
Guo X; Ma N; Wang J; Song J; Bu X; Cheng Y; Sun K; Xiong H; Jiang G; Zhang B; Wu M; Wei L
BMC Cancer; 2008 Dec; 8():375. PubMed ID: 19091131
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of mTOR suppresses human gallbladder carcinoma cell proliferation and enhances the cytotoxicity of 5-fluorouracil by downregulating MDR1 expression.
Li Q; Mou LJ; Tao L; Chen W; Sun XT; Xia XF; Wu XY; Shi XL
Eur Rev Med Pharmacol Sci; 2016 May; 20(9):1699-706. PubMed ID: 27212159
[TBL] [Abstract][Full Text] [Related]
14. Identification of GAS1 as an epirubicin resistance-related gene in human gastric cancer cells with a partially randomized small interfering RNA library.
Zhao L; Pan Y; Gang Y; Wang H; Jin H; Tie J; Xia L; Zhang Y; He L; Yao L; Qiao T; Li T; Liu Z; Fan D
J Biol Chem; 2009 Sep; 284(39):26273-85. PubMed ID: 19638344
[TBL] [Abstract][Full Text] [Related]
15. Interferon regulatory factor-1 reverses chemoresistance by downregulating the expression of P-glycoprotein in gastric cancer.
Yuan J; Yin Z; Tan L; Zhu W; Tao K; Wang G; Shi W; Gao J
Cancer Lett; 2019 Aug; 457():28-39. PubMed ID: 31078735
[TBL] [Abstract][Full Text] [Related]
16. An Anti-Cancer Drug Candidate OSI-027 and its Analog as Inhibitors of mTOR: Computational Insights Into the Inhibitory Mechanisms.
Rehan M
J Cell Biochem; 2017 Dec; 118(12):4558-4567. PubMed ID: 28475291
[TBL] [Abstract][Full Text] [Related]
17. β-Casein micelles for oral delivery of SN-38 and elacridar to overcome BCRP-mediated multidrug resistance in gastric cancer.
Bar-Zeev M; Kelmansky D; Assaraf YG; Livney YD
Eur J Pharm Biopharm; 2018 Dec; 133():240-249. PubMed ID: 30367935
[TBL] [Abstract][Full Text] [Related]
18. Isopetasin and S-isopetasin as novel P-glycoprotein inhibitors against multidrug-resistant cancer cells.
Abdelfatah S; Böckers M; Asensio M; Kadioglu O; Klinger A; Fleischer E; Efferth T
Phytomedicine; 2021 Jun; 86():153196. PubMed ID: 32229058
[TBL] [Abstract][Full Text] [Related]
19. The inhibitory effect of pseudolaric acid B on gastric cancer and multidrug resistance via Cox-2/PKC-α/P-gp pathway.
Sun Q; Li Y
PLoS One; 2014; 9(9):e107830. PubMed ID: 25250794
[TBL] [Abstract][Full Text] [Related]
20. GOLPH3 inhibition reverses oxaliplatin resistance of colon cancer cells via suppression of PI3K/AKT/mTOR pathway.
Yu T; An Q; Cao XL; Yang H; Cui J; Li ZJ; Xiao G
Life Sci; 2020 Nov; 260():118294. PubMed ID: 32818544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
